Patents by Inventor Fu-Tan Hsieh

Fu-Tan Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH DEUTERATED IMIDAZOQUINOLINES
    Publication number: 20240382469
    Abstract: The present specification provides therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 21, 2024
    Inventors: Pei-Jou LEE, Yi-Tsui CHIU, Fu-Tan HSIEH
  • Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses
    Patent number: 9775898
    Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 3, 2017
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
  • VACCINE COMPOSITION COMPRISING AN IMMUNOGENIC PROTEIN AND COMBINATION ADJUVANTS FOR USE IN ELICITING ANTIGEN-SPECIFIC T-CELL RESPONSES
    Publication number: 20160250324
    Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
    Type: Application
    Filed: February 24, 2016
    Publication date: September 1, 2016
    Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen